2021 共识指南:PCSK9抑制剂在脑卒中患者血管事件的二级预防中的应用

2021-12-11 国外神经内科相关专家小组(统称) Neurologia (Engl Ed)

具有卒中或短暂性脑缺血发作史的患者未来发生血管事件的风险较大,降低低密度脂蛋白(LDL)胆固醇水平可降低新血管事件的发生率。

中文标题:

2021 共识指南:PCSK9抑制剂在脑卒中患者血管事件的二级预防中的应用

英文标题:

Proprotein convertase subtilisin/kexin type 9 inhibitors in secondary prevention of vascular events in patients with stroke: Consensus document and practice guidance

发布日期:

2021-12-11

简要介绍:

具有卒中或短暂性脑缺血发作史的患者未来发生血管事件的风险较大,降低低密度脂蛋白(LDL)胆固醇水平可降低新血管事件的发生率。本文主要针对PCSK9抑制剂在脑卒中患者血管事件的二级预防中的应用提供最新指导建议。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2021 共识指南:PCSK9抑制剂在脑卒中患者血管事件的二级预防中的应用.pdf)] GetToolGuiderByIdResponse(projectId=1, id=a59cd1c002309625, title=2021 共识指南:PCSK9抑制剂在脑卒中患者血管事件的二级预防中的应用, enTitle=Proprotein convertase subtilisin/kexin type 9 inhibitors in secondary prevention of vascular events in patients with stroke: Consensus document and practice guidance, guiderFrom=Neurologia (Engl Ed), authorId=0, author=, summary=具有卒中或短暂性脑缺血发作史的患者未来发生血管事件的风险较大,降低低密度脂蛋白(LDL)胆固醇水平可降低新血管事件的发生率。, cover=https://img.medsci.cn/202211/1641024867573_1608702.png, journalId=0, articlesId=null, associationId=952, associationName=国外神经内科相关专家小组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Sat Dec 11 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">具有卒中或短暂性脑缺血发作史的患者未来发生血管事件的风险较大,降低低密度脂蛋白(LDL)胆固醇水平可降低新血管事件的发生率。本文主要针对PCSK9抑制剂在脑卒中患者血管事件的二级预防中的应用提供最新指导建议。</span></p>, tagList=[TagDto(tagId=64, tagName=脑卒中), TagDto(tagId=9418, tagName=神经系统疾病), TagDto(tagId=15123, tagName=PCSK9抑制剂)], categoryList=[CategoryDto(categoryId=17, categoryName=神经科, tenant=100), CategoryDto(categoryId=25, categoryName=神经外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=15123, guiderKeyword=PCSK9抑制剂, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=83604, appHits=144, showAppHits=0, pcHits=626, showPcHits=83460, likes=0, shares=9, comments=9, approvalStatus=1, publishedTime=Sat Jan 01 16:11:38 CST 2022, publishedTimeString=2021-12-11, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=dajiong, createdTime=Sat Jan 01 16:19:20 CST 2022, updatedBy=6415643, updatedName=凯晨, updatedTime=Sat Jan 06 19:32:19 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 共识指南:PCSK9抑制剂在脑卒中患者血管事件的二级预防中的应用.pdf)])
2021 共识指南:PCSK9抑制剂在脑卒中患者血管事件的二级预防中的应用.pdf
下载请点击:
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2154008, encodeId=4f9b21540086b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=949f8422746, createdName=ms5000000647577358, createdTime=Tue Aug 22 09:27:41 CST 2023, time=2023-08-22, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1217716, encodeId=f183121e71627, content=有没有中文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b9f8152264, createdName=ms5000001178338999, createdTime=Sat May 07 21:31:03 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214328, encodeId=708a1214328b4, content=<a href='/topic/show?id=6cdd13883c9' target=_blank style='color:#2F92EE;'>#PCSK9抑制剂#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13883, encryptionId=6cdd13883c9, topicName=PCSK9抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:35:59 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192712, encodeId=4fe81192e12f4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9be6495931, createdName=ms8000000018254969, createdTime=Sat Feb 12 17:25:51 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191349, encodeId=7d0011913496c, content=学习了,时刻关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc776147633, createdName=ms6000001364311142, createdTime=Wed Feb 09 09:40:52 CST 2022, time=2022-02-09, status=1, ipAttribution=)]
    2023-08-22 ms5000000647577358 来自湖南省

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2154008, encodeId=4f9b21540086b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=949f8422746, createdName=ms5000000647577358, createdTime=Tue Aug 22 09:27:41 CST 2023, time=2023-08-22, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1217716, encodeId=f183121e71627, content=有没有中文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b9f8152264, createdName=ms5000001178338999, createdTime=Sat May 07 21:31:03 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214328, encodeId=708a1214328b4, content=<a href='/topic/show?id=6cdd13883c9' target=_blank style='color:#2F92EE;'>#PCSK9抑制剂#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13883, encryptionId=6cdd13883c9, topicName=PCSK9抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:35:59 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192712, encodeId=4fe81192e12f4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9be6495931, createdName=ms8000000018254969, createdTime=Sat Feb 12 17:25:51 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191349, encodeId=7d0011913496c, content=学习了,时刻关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc776147633, createdName=ms6000001364311142, createdTime=Wed Feb 09 09:40:52 CST 2022, time=2022-02-09, status=1, ipAttribution=)]
    2022-05-07 ms5000001178338999

    有没有中文版

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2154008, encodeId=4f9b21540086b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=949f8422746, createdName=ms5000000647577358, createdTime=Tue Aug 22 09:27:41 CST 2023, time=2023-08-22, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1217716, encodeId=f183121e71627, content=有没有中文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b9f8152264, createdName=ms5000001178338999, createdTime=Sat May 07 21:31:03 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214328, encodeId=708a1214328b4, content=<a href='/topic/show?id=6cdd13883c9' target=_blank style='color:#2F92EE;'>#PCSK9抑制剂#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13883, encryptionId=6cdd13883c9, topicName=PCSK9抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:35:59 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192712, encodeId=4fe81192e12f4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9be6495931, createdName=ms8000000018254969, createdTime=Sat Feb 12 17:25:51 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191349, encodeId=7d0011913496c, content=学习了,时刻关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc776147633, createdName=ms6000001364311142, createdTime=Wed Feb 09 09:40:52 CST 2022, time=2022-02-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2154008, encodeId=4f9b21540086b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=949f8422746, createdName=ms5000000647577358, createdTime=Tue Aug 22 09:27:41 CST 2023, time=2023-08-22, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1217716, encodeId=f183121e71627, content=有没有中文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b9f8152264, createdName=ms5000001178338999, createdTime=Sat May 07 21:31:03 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214328, encodeId=708a1214328b4, content=<a href='/topic/show?id=6cdd13883c9' target=_blank style='color:#2F92EE;'>#PCSK9抑制剂#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13883, encryptionId=6cdd13883c9, topicName=PCSK9抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:35:59 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192712, encodeId=4fe81192e12f4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9be6495931, createdName=ms8000000018254969, createdTime=Sat Feb 12 17:25:51 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191349, encodeId=7d0011913496c, content=学习了,时刻关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc776147633, createdName=ms6000001364311142, createdTime=Wed Feb 09 09:40:52 CST 2022, time=2022-02-09, status=1, ipAttribution=)]
    2022-02-12 ms8000000018254969

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2154008, encodeId=4f9b21540086b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=949f8422746, createdName=ms5000000647577358, createdTime=Tue Aug 22 09:27:41 CST 2023, time=2023-08-22, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1217716, encodeId=f183121e71627, content=有没有中文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b9f8152264, createdName=ms5000001178338999, createdTime=Sat May 07 21:31:03 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214328, encodeId=708a1214328b4, content=<a href='/topic/show?id=6cdd13883c9' target=_blank style='color:#2F92EE;'>#PCSK9抑制剂#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13883, encryptionId=6cdd13883c9, topicName=PCSK9抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:35:59 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192712, encodeId=4fe81192e12f4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9be6495931, createdName=ms8000000018254969, createdTime=Sat Feb 12 17:25:51 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191349, encodeId=7d0011913496c, content=学习了,时刻关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc776147633, createdName=ms6000001364311142, createdTime=Wed Feb 09 09:40:52 CST 2022, time=2022-02-09, status=1, ipAttribution=)]
    2022-02-09 ms6000001364311142

    学习了,时刻关注

    0